These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2297204)

  • 1. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex.
    Hodges TL; Kahn JO; Kaplan LD; Groopman JE; Volberding PA; Amman AJ; Arri CJ; Bouvier LM; Mordenti J; Izu AE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2580-6. PubMed ID: 1810192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
    Collier AC; Coombs RW; Katzenstein D; Holodniy M; Gibson J; Mordenti J; Izu AE; Duliege AM; Ammann AJ; Merigan T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):150-6. PubMed ID: 7552478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146.
    Shearer WT; Duliege AM; Kline MW; Hammill H; Minkoff H; Ammann AJ; Chen S; Izu A; Mordenti J
    Clin Diagn Lab Immunol; 1995 May; 2(3):281-5. PubMed ID: 7664172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.
    Kahn JO; Kaplan LD; Gambertoglio JG; Bredesen D; Arri CJ; Turin L; Kibort T; Williams RL; Lifson JD; Volberding PA
    AIDS; 1990 Dec; 4(12):1197-204. PubMed ID: 2088398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
    Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
    Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
    Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
    Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
    J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    Abrams DI; Kuno S; Wong R; Jeffords K; Nash M; Molaghan JB; Gorter R; Ueno R
    Ann Intern Med; 1989 Feb; 110(3):183-8. PubMed ID: 2463780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS.
    Clerici M; Yarchoan R; Blatt S; Hendrix CW; Ammann AJ; Broder S; Shearer GM
    J Infect Dis; 1993 Oct; 168(4):1012-6. PubMed ID: 8376811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation.
    Crumpacker C; Heagy W; Bubley G; Monroe JE; Finberg R; Hussey S; Schnipper L; Lucey D; Lee TH; McLane MF
    Ann Intern Med; 1987 Nov; 107(5):664-74. PubMed ID: 3662279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll.
    Schwander S; Opravil M; Lüthy R; Hanson DG; Schindler J; Dawson A; Letwin B; Dietrich M
    Infection; 1994; 22(2):86-91. PubMed ID: 7915256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
    Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
    N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex.
    Kahn JO; Gorelick KJ; Gatti G; Arri CJ; Lifson JD; Gambertoglio JG; Bostrom A; Williams R
    Antimicrob Agents Chemother; 1994 Feb; 38(2):260-7. PubMed ID: 7910722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.